These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 35984843)
21. Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients. Azad AA; Eigl BJ; Murray RN; Kollmannsberger C; Chi KN Eur Urol; 2015 Jan; 67(1):23-29. PubMed ID: 25018038 [TBL] [Abstract][Full Text] [Related]
22. Treatment selection for men with metastatic prostate cancer who progress on upfront chemo-hormonal therapy. Barata P; Emamekhoo H; Mendiratta P; Koshkin V; Tyler A; Ornstein M; Rini BI; Gilligan T; Kyriakopoulos C; Garcia JA Prostate; 2018 Sep; 78(13):1035-1041. PubMed ID: 29882332 [TBL] [Abstract][Full Text] [Related]
23. Impact of next-generation hormonal agents on treatment patterns among patients with metastatic hormone-sensitive prostate cancer: a real-world study from the United States, five European countries and Japan. Leith A; Ribbands A; Kim J; Clayton E; Gillespie-Akar L; Yang L; Ghate SR BMC Urol; 2022 Mar; 22(1):33. PubMed ID: 35277153 [TBL] [Abstract][Full Text] [Related]
24. Treatment of Metastasized Prostate Cancer Beyond Progression After Upfront Docetaxel-A Real-world Data Assessment. Tsaur I; Heidegger I; van den Bergh RCN; Bektic J; Borgmann H; Foti S; Hunting JCB; Kretschmer A; Ploussard G; Tilki D; Gandaglia G; Dotzauer R; Eur Urol Focus; 2021 Nov; 7(6):1308-1315. PubMed ID: 32653263 [TBL] [Abstract][Full Text] [Related]
25. Comparative assessment of docetaxel for safety and efficacy between hormone-sensitive and castration-resistant metastatic prostate cancer. Mager R; Savko O; Böhm K; Thomas A; Dotzauer R; Borgmann H; Jäger W; Thomas C; Haferkamp A; Höfner T; Tsaur I Urol Oncol; 2019 Dec; 37(12):999-1005. PubMed ID: 31377168 [TBL] [Abstract][Full Text] [Related]
26. Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone. Suzman DL; Luber B; Schweizer MT; Nadal R; Antonarakis ES Prostate; 2014 Sep; 74(13):1278-85. PubMed ID: 25053178 [TBL] [Abstract][Full Text] [Related]
27. TEAM Study: Upfront Docetaxel Treatment in Patients With Metastatic Hormone-Sensitive Prostate Cancer: A Real-World, Multicenter, Retrospective Analysis. Pisano C; Turco F; Arnaudo E; Fea E; Vanella P; Ruatta F; Filippi R; Brusa F; Prati V; Vana F; Mennitto A; Cattrini C; Vignani F; Dionisio R; Icardi M; Guglielmini P; Buosi R; Stevani I; Vormola R; Numico G; Depetris I; Comandone A; Gennari A; Airoldi M; Rossi M; Vellani G; Ortega C; Tucci M; Maio MD; Buttigliero C Clin Genitourin Cancer; 2024 Apr; 22(2):56-67.e16. PubMed ID: 37798164 [TBL] [Abstract][Full Text] [Related]
28. Overall Survival After Systemic Treatment in High-volume Versus Low-volume Metastatic Hormone-sensitive Prostate Cancer: Systematic Review and Network Meta-analysis. Wenzel M; Würnschimmel C; Nocera L; Collà Ruvolo C; Tian Z; Shariat SF; Saad F; Briganti A; Tilki D; Graefen M; Kluth LA; Roos FC; Mandel P; Chun FKH; Karakiewicz PI Eur Urol Focus; 2022 Mar; 8(2):399-408. PubMed ID: 33853754 [TBL] [Abstract][Full Text] [Related]
29. PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: evidence from patients in Northwestern China. Wu KJ; Pei XQ; Tian G; Wu DP; Fan JH; Jiang YM; He DL Asian J Androl; 2018; 20(2):173-177. PubMed ID: 28905815 [TBL] [Abstract][Full Text] [Related]
30. Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC). Francini E; Gray KP; Xie W; Shaw GK; Valença L; Bernard B; Albiges L; Harshman LC; Kantoff PW; Taplin ME; Sweeney CJ Prostate; 2018 Sep; 78(12):889-895. PubMed ID: 29707790 [TBL] [Abstract][Full Text] [Related]
31. Comparison of Alternative Androgen Receptor-axis-targeted Agent (ARATA) and Docetaxel as Second-line Therapy for Patients With Metastatic Castration-resistant Prostate Cancer With Progression After Initial ARATA in Real-world Clinical Practice in Japan. Miyake H; Sugiyama T; Aki R; Matsushita Y; Tamura K; Motoyama D; Ito T; Otsuka A Clin Genitourin Cancer; 2018 Jun; 16(3):219-225. PubMed ID: 29274813 [TBL] [Abstract][Full Text] [Related]
32. Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer. Maughan BL; Xhou XC; Suzman DL; Nadal R; Bassi S; Schweizer MT; Antonarakis ES Prostate; 2015 Nov; 75(15):1814-20. PubMed ID: 26306637 [TBL] [Abstract][Full Text] [Related]
33. The Role of Fast and Deep PSA Response in Castration-sensitive Prostate Cancer. Iacovelli R; Ciccarese C; Caffo O; De Giorgi U; Basso U; Tucci M; Mosillo C; Maruzzo M; Maines F; Casadei C; Milella M; Tortora G Anticancer Res; 2022 Jan; 42(1):165-172. PubMed ID: 34969722 [TBL] [Abstract][Full Text] [Related]
34. The heterogeneity of intraductal carcinoma of the prostate is associated with different efficacy of standard first-line therapy for patients with metastatic castration-resistant prostate cancer. Wang Z; Zhu S; Zhao J; Nie L; Chen X; Zhang M; Chen N; Sun G; Chen J; Ni Y; Dai J; Liu Z; Tao R; Zhang X; Zhu X; Zhang H; Liang J; Wang Z; He B; Shen P; Zeng H Prostate; 2021 Nov; 81(15):1191-1201. PubMed ID: 34435696 [TBL] [Abstract][Full Text] [Related]
35. Upfront Androgen Receptor-Axis-Targeted Therapies in Men with De Novo High-Volume Metastatic Hormone-Sensitive Prostate Cancer. Kimura N; Kaneko Y; Tetsuka T; Takei A; Uchida T; Abe H; Amiya Y; Shima T; Suzuki N; Hayashi S; Nakatsu H Urol J; 2023 Jul; 20(4):222-228. PubMed ID: 36906797 [TBL] [Abstract][Full Text] [Related]
36. Real-world analysis of metastatic prostate cancer demonstrates increased frequency of PSA-imaging discordance with visceral metastases and upfront ARAT/docetaxel therapy. Hara T; Terakawa T; Okamura Y; Bando Y; Furukawa J; Harada K; Nakano Y; Fujisawa M Prostate; 2023 Sep; 83(13):1270-1278. PubMed ID: 37316357 [TBL] [Abstract][Full Text] [Related]
37. PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: Multicenter validation in patients from the Chinese Prostate Cancer Consortium. Pei X; Wu K; Sun Y; Gao X; Gou X; Xu J; Gao F; He D; Li L; Urol Oncol; 2020 Jan; 38(1):2.e11-2.e17. PubMed ID: 31672485 [TBL] [Abstract][Full Text] [Related]
38. Outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status. Azad AA; Eigl BJ; Leibowitz-Amit R; Lester R; Kollmannsberger C; Murray N; Clayton R; Heng DY; Joshua AM; Chi KN Eur Urol; 2015 Mar; 67(3):441-7. PubMed ID: 24508071 [TBL] [Abstract][Full Text] [Related]
39. Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate. Thomsen FB; Røder MA; Rathenborg P; Brasso K; Borre M; Iversen P Scand J Urol; 2014 Jun; 48(3):268-75. PubMed ID: 24255983 [TBL] [Abstract][Full Text] [Related]
40. Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer. Zhang T; Dhawan MS; Healy P; George DJ; Harrison MR; Oldan J; Chin B; Armstrong AJ Clin Genitourin Cancer; 2015 Aug; 13(4):392-399. PubMed ID: 25708161 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]